C̲̲Z🔸 (@AItalianoMD) profile picture
Bordeaux and Villejuif, France
Joined February 2017
The relentless quest for biomarkers predicting the outcome of immune-checkpoint blockade: 👉in press in Annals of Oncology, plasma proteomics identify Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of resistance annalsofoncology.org/article… @GustaveRoussy @y_loriot
Plasma proteomics identifies Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance annalsofoncology.org/article…
2
3
Fascinating paper investigating the gene expression program of mutation associated neoantigen-specific -TIL in cancer patients treated with ICI. Detectable in a majority of patients (Blood and tissue)
1
4
Nice paper showing the immunomodulatory of PARP7, a new target to improve efficacy of ICI
3
5
Opening the black box of undifferentiated pleomorphic sarcomas authors.elsevier.com/sd/arti…
2
9
Identifying DNA Repair gene mutations beyond BRCA may have a strong clinical impact authors.elsevier.com/a/1b3ea…
1
1
Molecular profiling results are biased by undersampling. Sequencing of usually discarded tumor material improve the accuracy of molecular data.
4
7
Up to 25% of Sarcoma patients have monogenic or polygenic variants in DDR genes. DDR targeting deserves more investigation in this devastating group of diseases.
5
9
Presence of tertiary lymphoid structures as a predictive biomarker of immune-checkpoint inhibitors benefit in sarcomas: moving toward personalized immunotherapy for our patients
8
17
1st Molecular Tumor Board of the MULTISARC study. Proud of the team who did an amazing work to make this study feasible. Thanks to INSERM and French Sarcoma Group
1
17
2018 Annual meeting of the French Sarcoma Group in Montpellier. Friendly atmosphere, productive collaboration.
1
6
16
High rate of DDR genes alterations and occurence of BRAF in frame deletions sensitive to MEK inhibition in pancreatic cancer : moving forward precision medicine
9
10
Thousands of people celebrating "the wine" in Bordeaux. Fantastic event but missed opportunity to inform about the risks of an overconsumption.
2
IFODS 2018: Wonderful talk from Bob Maki about the potential of immunotherapy in sarcomas
3
9
High-risk localized sarcoma patients deserve neoadjuvant chemotherapy
2
Moving forward precision medicine in sarcomas
2
5
Early phase studies associated with significant clinical benefit for cancer patients
4
9
A Cancer Conundrum: Too Many Drug Trials, Too Few Patients nyti.ms/2vsMRXfp an US problem ? In France: not enough drug trials !
1
4
9